Melior Pharmaceuticals said that based upon results of its Phase 2 clinical study with Bukwang Pharmaceuticalds, a milestone has been achieved and as a result the partners will advance the compound into an additional Phase 2 clinical study. This event also triggers a success milestone to Melior. The 4-week protocol enrolled 130 diabetic subjects across 19 clinical sites in the U.S. and Korea. Based on the safety and efficacy exhibited by MLR-1023, the partners are progressing the compound int...